Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.
Wissam GhusnSima FansaDiego AnazcoElif TamaBryan NicolaldeKhushboo GalaAlan De la RosaDaniel SacotoLizeth CifuentesAlejandro CamposFauzi FeresMaria Daniela Hurtado AAndres AcostaPublished in: International journal of obesity (2005) (2024)
Semaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.